IOL Chemicals and Pharmaceuticals Past Earnings Performance
Past criteria checks 2/6
IOL Chemicals and Pharmaceuticals's earnings have been declining at an average annual rate of -21.7%, while the Pharmaceuticals industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 5% per year. IOL Chemicals and Pharmaceuticals's return on equity is 8.3%, and it has net margins of 6.3%.
Key information
-21.7%
Earnings growth rate
-22.6%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | 5.0% |
Return on equity | 8.3% |
Net Margin | 6.3% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How IOL Chemicals and Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 21,328 | 1,344 | 2,010 | 0 |
31 Dec 23 | 22,161 | 1,716 | 1,938 | 0 |
30 Sep 23 | 22,192 | 1,723 | 1,873 | 0 |
30 Jun 23 | 22,153 | 1,503 | 1,787 | 0 |
31 Mar 23 | 22,171 | 1,391 | 1,686 | 0 |
31 Dec 22 | 22,024 | 1,041 | 1,633 | 0 |
30 Sep 22 | 22,341 | 1,204 | 1,567 | 0 |
30 Jun 22 | 22,305 | 1,353 | 1,518 | 0 |
31 Mar 22 | 21,840 | 1,677 | 1,415 | 0 |
31 Dec 21 | 20,719 | 2,132 | 1,350 | 0 |
30 Sep 21 | 20,298 | 2,879 | 1,280 | 0 |
30 Jun 21 | 20,254 | 3,840 | 1,251 | 0 |
31 Mar 21 | 19,670 | 4,446 | 1,157 | 0 |
31 Dec 20 | 19,481 | 4,596 | 1,104 | 0 |
30 Sep 20 | 19,463 | 4,428 | 1,062 | 0 |
30 Jun 20 | 18,618 | 4,035 | 975 | 0 |
31 Mar 20 | 18,945 | 3,613 | 974 | 0 |
31 Dec 19 | 18,753 | 3,727 | 923 | 0 |
30 Sep 19 | 18,423 | 3,569 | 904 | 0 |
30 Jun 19 | 18,163 | 3,076 | 855 | 0 |
31 Mar 19 | 16,853 | 2,367 | 794 | 0 |
31 Dec 18 | 15,506 | 1,465 | 736 | 0 |
30 Sep 18 | 13,350 | 731 | 657 | 0 |
30 Jun 18 | 11,298 | 391 | 605 | 0 |
31 Mar 18 | 9,833 | 277 | 562 | 0 |
31 Dec 17 | 8,891 | 178 | 526 | 0 |
30 Sep 17 | 8,094 | 100 | 495 | 0 |
30 Jun 17 | 8,265 | 65 | 26 | 0 |
31 Mar 17 | 7,107 | 47 | 433 | 0 |
31 Dec 16 | 6,595 | 39 | 436 | 0 |
30 Sep 16 | 6,197 | -74 | 407 | 0 |
30 Jun 16 | 6,055 | -214 | 382 | 0 |
31 Mar 16 | 5,804 | -400 | 352 | 0 |
31 Dec 15 | 5,131 | -692 | 386 | 0 |
30 Sep 15 | 4,377 | -890 | 363 | 0 |
30 Jun 15 | 4,008 | -858 | 261 | 0 |
31 Mar 15 | 3,847 | -667 | 248 | 0 |
31 Dec 14 | 4,405 | -378 | 277 | 0 |
30 Sep 14 | 5,115 | -71 | 281 | 0 |
30 Jun 14 | 5,452 | 37 | 271 | 0 |
31 Mar 14 | 5,635 | 33 | 398 | 0 |
31 Dec 13 | 5,684 | 26 | 267 | 0 |
30 Sep 13 | 5,466 | 23 | 256 | 0 |
Quality Earnings: 524164 has high quality earnings.
Growing Profit Margin: 524164's current net profit margins (6.3%) are higher than last year (6.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524164's earnings have declined by 21.7% per year over the past 5 years.
Accelerating Growth: 524164's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 524164 had negative earnings growth (-3.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (18.2%).
Return on Equity
High ROE: 524164's Return on Equity (8.3%) is considered low.